IL101858A - Pharmaceutical preparations containing a combination of angiotensin-II and calcium channel blocker - Google Patents
Pharmaceutical preparations containing a combination of angiotensin-II and calcium channel blockerInfo
- Publication number
- IL101858A IL101858A IL10185892A IL10185892A IL101858A IL 101858 A IL101858 A IL 101858A IL 10185892 A IL10185892 A IL 10185892A IL 10185892 A IL10185892 A IL 10185892A IL 101858 A IL101858 A IL 101858A
- Authority
- IL
- Israel
- Prior art keywords
- combination
- angiotensin
- calcium channel
- antagonist
- channel blocker
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70074091A | 1991-05-15 | 1991-05-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
IL101858A0 IL101858A0 (en) | 1992-12-30 |
IL101858A true IL101858A (en) | 1996-08-04 |
Family
ID=24814683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL10185892A IL101858A (en) | 1991-05-15 | 1992-05-14 | Pharmaceutical preparations containing a combination of angiotensin-II and calcium channel blocker |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0584250A1 (ja) |
JP (1) | JP2930252B2 (ja) |
AU (1) | AU664375B2 (ja) |
CA (1) | CA2103276A1 (ja) |
CZ (1) | CZ281570B6 (ja) |
IE (1) | IE921534A1 (ja) |
IL (1) | IL101858A (ja) |
MX (1) | MX9202243A (ja) |
NZ (1) | NZ242724A (ja) |
WO (1) | WO1992020342A1 (ja) |
ZA (1) | ZA923557B (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3057471B2 (ja) | 1993-06-07 | 2000-06-26 | 武田薬品工業株式会社 | アンジオテンシンii介在性諸疾患の予防または治療剤 |
JP3883205B2 (ja) * | 1994-03-29 | 2007-02-21 | メルク エンド カンパニー インコーポレーテッド | アンギオテンシン▲ii▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療 |
DE69626958T2 (de) | 1995-03-16 | 2004-03-18 | Pfizer Inc. | Verwendung von amlodipin, eines seiner salze oder felodipin in kombination mit einem ace-hemmer zur herstellung eines arzneimittels zur behandlung von nicht ischämischer kongestiver herzinsuffizienz |
US6204281B1 (en) | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
DE69936992T2 (de) | 1998-07-10 | 2008-03-06 | Novartis Pharma Ag | Bluthochdruckgegenmittelkombination des valsartan und kalziumkanal blocker |
US7481803B2 (en) * | 2000-11-28 | 2009-01-27 | Flowmedica, Inc. | Intra-aortic renal drug delivery catheter |
US6395728B2 (en) | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
JP4000505B2 (ja) * | 1999-12-01 | 2007-10-31 | 第一三共株式会社 | 緑内障を治療するための併用剤 |
GB0008332D0 (en) * | 2000-04-04 | 2000-05-24 | Pfizer Ltd | Treament |
WO2001082858A2 (de) * | 2000-05-04 | 2001-11-08 | Ipf Pharmaceuticals Gmbh | Neue verbindungen zur behandlung inflammatorischer und kardiovaskulärer erkrankungen |
CA2430924A1 (en) * | 2000-12-01 | 2002-06-06 | Novartis Ag | Angiotensin receptor antagonist composition for the treatment of sexual dysfunction associated with hypertension and another condition |
EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
EP3045174A1 (en) * | 2003-01-31 | 2016-07-20 | Daiichi Sankyo Company, Limited | Medicine for prevention of and treatment for arteriosclerosis and hypertension |
TW200833325A (en) * | 2006-12-26 | 2008-08-16 | Daiichi Sankyo Co Ltd | Pharmaceutical composition comprising ascorbic acid |
WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
AU2009256157B2 (en) | 2008-06-04 | 2014-12-18 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2607004B1 (fr) * | 1986-11-20 | 1990-06-01 | Synthelabo | Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine |
US5015651A (en) * | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
CA2020073A1 (en) * | 1989-07-03 | 1991-01-04 | Eric E. Allen | Substituted quinazolinones as angiotensin ii antagonists |
EP0565634B1 (en) * | 1990-12-14 | 1999-03-17 | Smithkline Beecham Corporation | Angiotensin ii receptor blocking compositions |
-
1992
- 1992-05-13 NZ NZ242724A patent/NZ242724A/xx not_active IP Right Cessation
- 1992-05-14 CA CA002103276A patent/CA2103276A1/en not_active Abandoned
- 1992-05-14 EP EP92912707A patent/EP0584250A1/en not_active Withdrawn
- 1992-05-14 WO PCT/US1992/003873 patent/WO1992020342A1/en not_active Application Discontinuation
- 1992-05-14 AU AU20269/92A patent/AU664375B2/en not_active Expired
- 1992-05-14 IL IL10185892A patent/IL101858A/en not_active IP Right Cessation
- 1992-05-14 JP JP5500110A patent/JP2930252B2/ja not_active Expired - Lifetime
- 1992-05-14 CZ CS932351A patent/CZ281570B6/cs not_active IP Right Cessation
- 1992-05-14 MX MX9202243A patent/MX9202243A/es unknown
- 1992-05-15 ZA ZA923557A patent/ZA923557B/xx unknown
- 1992-07-01 IE IE153492A patent/IE921534A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CZ281570B6 (cs) | 1996-11-13 |
AU2026992A (en) | 1992-12-30 |
JPH06508128A (ja) | 1994-09-14 |
AU664375B2 (en) | 1995-11-16 |
NZ242724A (en) | 1994-09-27 |
JP2930252B2 (ja) | 1999-08-03 |
WO1992020342A1 (en) | 1992-11-26 |
MX9202243A (es) | 1992-11-01 |
CA2103276A1 (en) | 1992-11-16 |
EP0584250A1 (en) | 1994-03-02 |
EP0584250A4 (ja) | 1994-03-30 |
ZA923557B (en) | 1993-11-15 |
IE921534A1 (en) | 1992-11-18 |
IL101858A0 (en) | 1992-12-30 |
CZ235193A3 (en) | 1994-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL101858A (en) | Pharmaceutical preparations containing a combination of angiotensin-II and calcium channel blocker | |
US5492904A (en) | Composition of angiotensin-II receptor antagonists and calcium channel blockers | |
EP0565634B1 (en) | Angiotensin ii receptor blocking compositions | |
US5958961A (en) | Pharmaceutical composition for angiotensin II-mediated diseases | |
EP0628313B1 (en) | Combination of an angiotensin-II antagonising benzimidazole with manidipine for the treatment of hypertension | |
HU219404B (hu) | Eljárás kardiális és vaszkuláris hipertrófia és/vagy hiperplazia kezelésére alkalmas angiotenzin-II-receptor blokkoló hatású vegyületet tartalmazó gyógyszerkészítmények előállítására | |
EP1909757A2 (en) | Oral liquid losartan compositions | |
AU2006215583B2 (en) | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics | |
NZ514058A (en) | Medicament for treating hypertension | |
JP3057471B2 (ja) | アンジオテンシンii介在性諸疾患の予防または治療剤 | |
AU716519B2 (en) | Method of treating renal disease using an ace inhibitor and an A II antagonist | |
EP0368972B1 (en) | Method of safely providing anesthesia or conscious sedation | |
KR20090094285A (ko) | 용출성 개선 방법 | |
KR100222627B1 (ko) | 앙기오텐신-ii 수용체 길항제 및 칼슘 채널 차단제의 신규한 조성물 | |
CA2459017A1 (en) | Medicinal compositions containing angiotensin ii receptor antagonist | |
JPH01275529A (ja) | 晩発性運動障害の抑制治療剤 | |
JPH02121925A (ja) | 腎ドーパミン様作用剤とアンジオテンシン変換酵素抑制剤の相乗作用を有する組成物 | |
IE900233L (en) | Low dose benazepril/thiazide diuretic composition | |
GB2227664A (en) | Treating hypertension using a thromboxane A2 receptor antagonist | |
Schoenberger | Calcium antagonists: use in hypertension evaluation of calcium antagonists in combination with diuretics. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |